RogCon Biosciences, Inc.
https://www.rogcon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RogCon Biosciences, Inc.
Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- RogCon U.R.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice